Drug-Associated Heart Infection Hospitalizations Decline
Hospitalizations dropped 18% since 2020, though clinicians see a rising share of cases involving stimulant use.
Updated on Oct. 27, 2026 in Substance Abuse
Live Poll
Should the healthcare system prioritize more resources for treating stimulant use disorder?
Hospitalizations for drug-associated infective endocarditis in the United States dropped 18% between 2020 and 2022. While overall cases declined, stimulant involvement in these heart valve infections rose to 47% during the same period.
Why it matters
Infective endocarditis is a serious heart infection often caused by bacteria entering the bloodstream through injection drug use. This shift toward stimulants presents a new challenge for providers, particularly as there are currently no FDA-approved medications to treat stimulant use disorder.
This retrospective analysis of over 118,000 hospitalizations from 2016 to 2022 documented an 18% decline in cases since 2020. However, the study observed that stimulant involvement climbed from 37% in 2016 to 47% by 2022, with regional rates reaching 59% in the Pacific.
The details
Infective endocarditis occurs when bacteria enter the circulatory system and infect the inner heart lining or valves, frequently damaging them. While opioid-associated cases may have decreased due to broader access to addiction treatment and harm reduction services, the rising prevalence of stimulant involvement reflects a changing clinical landscape. Researchers suggest that shifts in drug administration methods, such as moving from injection to smoking, might contribute to varying infection risks, though further study is needed.
Timeline
2016 marked the start of the study period when stimulants were linked to 37% of cases.
2020 saw hospitalizations peak at approximately 18,700 cases.
2022 records show hospitalizations declined to 15,300 with 47% involving stimulants.
Health Landscape
This data highlights an evolving crisis that complicates the standard of care for serious heart infections. It follows recent efforts under the National Institutes of Health's stimulant use disorder research priorities to address the current lack of FDA-approved pharmacological treatments.
Individuals who use substances should be aware that heart infections remain a severe risk, even if specific injection methods are changing. If you have concerns about substance use or health-related complications, discuss these risks and potential harm reduction services with your physician.
The takeaway
While hospitalizations for endocarditis are trending downward, the rise of stimulant involvement requires patients and doctors to remain vigilant regarding heart health. Always disclose substance use to your medical team to ensure they can effectively screen for heart valve complications and other risks.
Further reading
For more on the current approach to treatment, see the Substance Abuse section.
More information
You can review the full clinical study to learn more about the findings.
Live Poll
Should the healthcare system prioritize more resources for treating stimulant use disorder?
